Optimized Response-Adaptive Clinical Trials: Sequential Treatment Allocation Based on Markov Decision Problems by Thomas OndraOptimized Response-Adaptive Clinical Trials: Sequential Treatment Allocation Based on Markov Decision Problems by Thomas Ondra

Optimized Response-Adaptive Clinical Trials: Sequential Treatment Allocation Based on Markov…

byThomas Ondra

Paperback | December 18, 2014

Pricing and Purchase Info

$87.31 online 
$113.95 list price save 23%
Earn 437 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

Two-armed response-adaptive clinical trials are modelled as Markov decision problems to pursue two overriding objectives: Firstly, to identify the superior treatment at the end of the trial and, secondly, to keep the number of patients receiving the inferior treatment small. Such clinical trial designs are very important, especially for rare diseases. Thomas Ondra presents the main solution techniques for Markov decision problems and provides a detailed description how to obtain optimal allocation sequences.
Thomas Ondra obtained his Master of Science degree in mathematics at University of Vienna. He is a research assistant and PhD student at the Section for Medical Statistics of Medical University of Vienna.
Loading
Title:Optimized Response-Adaptive Clinical Trials: Sequential Treatment Allocation Based on Markov…Format:PaperbackDimensions:102 pagesPublished:December 18, 2014Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3658083433

ISBN - 13:9783658083434

Reviews

Table of Contents

Introduction to Markov Decision Problems and Examples.- Finite and Infinite Horizon Markov Decision Problems.- Solution Algorithms: Backward Induction, Value Iteration and Policy Iteration.- Designing Response Adaptive Clinical Trials with Markov Decision Problems.

Editorial Reviews

"It is a remarkably concise exposition of the use ofMDPs in a pharmaceutical setting; as such, the book's audience is theintersection of researchers and students with a sophisticated mathematicalbackground and professionals in the pharmaceutical industry. . the book is avery sophisticated treatise on MDP models for managing response-adaptiveclinical trials and both mathematicians and pharmaceutical professionals wouldappreciate it." (James Smith, Interfaces, Vol. 45 (4), July-August, 2015)